SNRS- Sunrise Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies

SNRS 0.000001000

0.0%

Jun 6 11:01 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bruce L who wrote (2115)	2/23/1999 4:41:00 PM
From: RockDoc	Read Replies (1) of 4140

What's to say? The report is full of inaccuracies as has been pointed out by others on the Yahoo thread. It's most basic assertions are erroneous: 1) The regression data is old data from earlier clinical trial cohort 2) The assumption that LASIK will be the treatment of choice for correction of low to mid hyperopia. I guess we'll have to let the marketplace make that decision. 3) The implication that there has been some wrong-doing by SNRS by the fact that several of the principal investigators are large company shareholders. There has been no FDA violations that I am aware of. Also that SNRS allegedly made representations in some press releases based upon FDA regulations. I am not aware that this has been the case. 4) The opinions of WORLDWIDE VISION CARE COMPANIES (like the competition is going to say how great LTK really is); the European Association of Ophthalmologists (all looking at old protoype-driven data); "NUMEROUS DOCTORS INVOLVED IN REFRACTIVE SURGERY" (would they care to list them and their respective holdings?) and a member of team that performed first LASIK (gee, what a surprise). Anyway, the report is there for anyone to digest. I personally will continue to trust the opinions of those ophthalmologists involved in directly in the clinical trials who have put their own money on the line by purchasing stock because they know and believe in the future success of the LTK technology. At least MFC acknowledges that the FDA will approve, and there is not a shred of doubt raised about that fact. If I'm the patient, and I have a choice between LASKIK and LTK to correct my farsightedness, it is a no-brainer decision. I'm banking that it will be a no-brainer decision for the marketplace, too. The ROCKSTER

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next